Marathon Trading Investment Management LLC Purchases Shares of 15,654 DexCom, Inc. (NASDAQ:DXCM)

Marathon Trading Investment Management LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,654 shares of the medical device company’s stock, valued at approximately $1,217,000.

A number of other hedge funds have also recently made changes to their positions in the business. Versant Capital Management Inc purchased a new position in DexCom in the 4th quarter worth $25,000. Private Trust Co. NA boosted its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares during the period. Larson Financial Group LLC grew its stake in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in shares of DexCom in the fourth quarter worth about $38,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of DexCom in the 4th quarter valued at about $49,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Down 9.1 %

DXCM stock opened at $70.72 on Tuesday. The company has a market capitalization of $27.64 billion, a price-to-earnings ratio of 49.45, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The business’s 50 day moving average price is $84.68 and its two-hundred day moving average price is $77.00. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent research reports. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Citigroup raised their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Morgan Stanley upped their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Insider Transactions at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock valued at $3,309,794 in the last three months. 0.30% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.